×
S&P 500   3,813.34 (-0.21%)
DOW   31,016.68 (+0.23%)
QQQ   284.35 (+0.29%)
AAPL   139.96 (+1.83%)
MSFT   261.58 (+1.99%)
META   163.40 (+1.69%)
GOOGL   2,225.41 (-0.66%)
AMZN   109.38 (+1.84%)
TSLA   681.03 (-2.43%)
NVDA   154.56 (-3.29%)
NIO   21.65 (-3.18%)
BABA   115.46 (-1.11%)
AMD   77.65 (-3.87%)
MU   55.75 (-3.65%)
CGC   3.52 (-2.49%)
T   20.99 (+1.84%)
GE   63.59 (-3.48%)
F   11.52 (-2.46%)
DIS   95.79 (-0.14%)
AMC   13.55 (+1.27%)
PFE   51.23 (+1.13%)
PYPL   71.29 (-0.74%)
NFLX   177.33 (-1.26%)
S&P 500   3,813.34 (-0.21%)
DOW   31,016.68 (+0.23%)
QQQ   284.35 (+0.29%)
AAPL   139.96 (+1.83%)
MSFT   261.58 (+1.99%)
META   163.40 (+1.69%)
GOOGL   2,225.41 (-0.66%)
AMZN   109.38 (+1.84%)
TSLA   681.03 (-2.43%)
NVDA   154.56 (-3.29%)
NIO   21.65 (-3.18%)
BABA   115.46 (-1.11%)
AMD   77.65 (-3.87%)
MU   55.75 (-3.65%)
CGC   3.52 (-2.49%)
T   20.99 (+1.84%)
GE   63.59 (-3.48%)
F   11.52 (-2.46%)
DIS   95.79 (-0.14%)
AMC   13.55 (+1.27%)
PFE   51.23 (+1.13%)
PYPL   71.29 (-0.74%)
NFLX   177.33 (-1.26%)
S&P 500   3,813.34 (-0.21%)
DOW   31,016.68 (+0.23%)
QQQ   284.35 (+0.29%)
AAPL   139.96 (+1.83%)
MSFT   261.58 (+1.99%)
META   163.40 (+1.69%)
GOOGL   2,225.41 (-0.66%)
AMZN   109.38 (+1.84%)
TSLA   681.03 (-2.43%)
NVDA   154.56 (-3.29%)
NIO   21.65 (-3.18%)
BABA   115.46 (-1.11%)
AMD   77.65 (-3.87%)
MU   55.75 (-3.65%)
CGC   3.52 (-2.49%)
T   20.99 (+1.84%)
GE   63.59 (-3.48%)
F   11.52 (-2.46%)
DIS   95.79 (-0.14%)
AMC   13.55 (+1.27%)
PFE   51.23 (+1.13%)
PYPL   71.29 (-0.74%)
NFLX   177.33 (-1.26%)
S&P 500   3,813.34 (-0.21%)
DOW   31,016.68 (+0.23%)
QQQ   284.35 (+0.29%)
AAPL   139.96 (+1.83%)
MSFT   261.58 (+1.99%)
META   163.40 (+1.69%)
GOOGL   2,225.41 (-0.66%)
AMZN   109.38 (+1.84%)
TSLA   681.03 (-2.43%)
NVDA   154.56 (-3.29%)
NIO   21.65 (-3.18%)
BABA   115.46 (-1.11%)
AMD   77.65 (-3.87%)
MU   55.75 (-3.65%)
CGC   3.52 (-2.49%)
T   20.99 (+1.84%)
GE   63.59 (-3.48%)
F   11.52 (-2.46%)
DIS   95.79 (-0.14%)
AMC   13.55 (+1.27%)
PFE   51.23 (+1.13%)
PYPL   71.29 (-0.74%)
NFLX   177.33 (-1.26%)
NYSEAMERICAN:ISR

Isoray Stock Forecast, Price & News

$0.28
+0.01 (+2.96%)
(As of 06/29/2022 01:09 PM ET)
Add
Compare
Today's Range
$0.28
$0.29
50-Day Range
N/A
52-Week Range
$0.25
$0.82
Volume
4,200 shs
Average Volume
385,812 shs
Market Capitalization
$39.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.25
30 days | 90 days | 365 days | Advanced Chart

Receive ISR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Isoray and its competitors with MarketBeat's FREE daily newsletter.

ISR Stock Forecast (MarketRank)

Overall MarketRank

2.24 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
Isoray logo

About Isoray (NYSEAMERICAN:ISR)

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.

ISR Stock News Headlines

Form 424B5 Isoray, Inc. - StreetInsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:ISR
Previous Symbol
NYSEMKT:ISR
Employees
61
Year Founded
N/A

Company Calendar

Last Earnings
5/10/2022
Today
6/29/2022
Fiscal Year End
6/30/2022
Next Earnings (Estimated)
9/19/2022

Price Target and Rating

Average Stock Price Forecast
$1.25
High Stock Price Forecast
$1.25
Low Stock Price Forecast
$1.25
Forecasted Upside/Downside
+349.6%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
1 Analysts

Profitability

Net Income
$-3.39 million
Pretax Margin
-48.05%

Debt

Sales & Book Value

Annual Sales
$10.05 million
Book Value
$0.48 per share

Miscellaneous

Free Float
138,481,000
Market Cap
$39.49 million
Optionable
Not Optionable
Beta
0.92














Isoray Frequently Asked Questions

Should I buy or sell Isoray stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Isoray in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Isoray stock.
View analyst ratings for Isoray
or view top-rated stocks.

What is Isoray's stock price forecast for 2022?

1 Wall Street research analysts have issued 1-year price targets for Isoray's shares. Their ISR stock forecasts range from $1.25 to $1.25. On average, they anticipate Isoray's stock price to reach $1.25 in the next year. This suggests a possible upside of 349.6% from the stock's current price.
View analysts' price targets for Isoray
or view top-rated stocks among Wall Street analysts.

How has Isoray's stock price performed in 2022?

Isoray's stock was trading at $0.38 at the beginning of 2022. Since then, ISR stock has decreased by 26.8% and is now trading at $0.2780.
View the best growth stocks for 2022 here
.

When is Isoray's next earnings date?

Isoray is scheduled to release its next quarterly earnings announcement on Monday, September 19th 2022.
View our earnings forecast for Isoray
.

How were Isoray's earnings last quarter?

Isoray, Inc. (NYSEAMERICAN:ISR) posted its quarterly earnings data on Tuesday, May, 10th. The healthcare company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). The healthcare company had revenue of $2.91 million for the quarter, compared to analysts' expectations of $3.15 million. Isoray had a negative net margin of 48.05% and a negative trailing twelve-month return on equity of 9.19%.
View Isoray's earnings history
.

Who are Isoray's key executives?

Isoray's management team includes the following people:
  • Ms. Lori A. Holmes-Woods, CEO & Director (Age 60, Pay $371.19k)
  • Ms. Jennifer Streeter, COO & VP of HR (Age 52, Pay $266.35k)
  • Mr. William A. Cavanagh III, Chief R&D Officer (Age 56, Pay $253.34k)
  • Mr. Jonathan R. Hunt, CFO & Co-Principal Financial Officer (Age 55)
  • Mr. Mark J. Austin CPA, VP of Fin., Controller, Co-Principal Financial, Principal Accounting Officer & Sec. (Age 35)
  • Ms. Krista Cline, Sr. Director of Operations & Corp. Sec. (Age 40)

What other stocks do shareholders of Isoray own?

What is Isoray's stock symbol?

Isoray trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."

Who are Isoray's major shareholders?

Isoray's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bard Associates Inc. (0.47%), State Street Corp (0.39%), Taylor & Morgan Wealth Management LLC (0.39%) and Renaissance Technologies LLC (0.29%). Company insiders that own Isoray stock include Jonathan Robert Hunt, Lori A Woods, Mark John Austin, Michael Krachon, Philip J Vitale and William Cavanagh.
View institutional ownership trends for Isoray
.

Which major investors are selling Isoray stock?

ISR stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Isoray
or view top insider-selling stocks.

Which major investors are buying Isoray stock?

ISR stock was purchased by a variety of institutional investors in the last quarter, including Taylor & Morgan Wealth Management LLC, Bard Associates Inc., and State Street Corp. Company insiders that have bought Isoray stock in the last two years include Jonathan Robert Hunt, Lori A Woods, Mark John Austin, Michael Krachon, and Philip J Vitale.
View insider buying and selling activity for Isoray
or or view top insider-buying stocks.

How do I buy shares of Isoray?

Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Isoray's stock price today?

One share of ISR stock can currently be purchased for approximately $0.28.

How much money does Isoray make?

Isoray (NYSEAMERICAN:ISR) has a market capitalization of $39.49 million and generates $10.05 million in revenue each year. The healthcare company earns $-3.39 million in net income (profit) each year or ($0.05) on an earnings per share basis.

How many employees does Isoray have?

Isoray employs 61 workers across the globe.

How can I contact Isoray?

Isoray's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The official website for Isoray is isoray.com. The healthcare company can be reached via phone at (509) 375-1202, via email at [email protected], or via fax at 509-267-3670.

This page (NYSEAMERICAN:ISR) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.